OXBRIDGE RE HOLDINGS Ltd (OXBR) stock
Close on Nov 18, 2026Market cap $5.86MP/E 36.0Yield –
OXBRIDGE RE HOLDINGS Ltd grew revenue 40.4% to $2.78M over the twelve months to Jun 30, 2026. Free cash flow was -$1.36M. At the latest close the market valued the company at $5.86M, 36.0 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $5.86M
- P/E ratio
- 36.0
- Price to sales
- 2.11
- Price to book
- 0.89
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $2.78M
- Net income
- $131.00K
- EPS, diluted
- $0.02
- Free cash flow
- -$1.36M
- Book value per share
- $0.81
- Diluted shares
- 8M
Trading
- Next earnings
- Mar 29, 2027 (estimated, during market hours)
- Previous close
- $0.72
- Open
- $0.72
- Day's range
- $0.71 – $0.73
- Volume
- 2,961
- Average volume (20 days)
- 16,851
- Beta (5 years)
- 1.25
- 52-week range
- $0.65 – $1.86
- RSI (14 days)
- 36.5
- Volatility (1 year)
- 104.3%
- Relative volume
- 0.09×
- WACC
- 11.4%
Market cap history
Month-end market cap since 2014, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 18, 2026. The S&P 500 is measured by the SPY fund.
| Period | OXBR | S&P 500 | Difference | OXBR per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -28.0% | -4.3% | −23.6 pts | ||
| 3 months | -46.6% | -4.6% | −42.0 pts | ||
| Year to date | -45.4% | +7.9% | −53.3 pts | ||
| 1 year | -40.5% | +11.8% | −52.3 pts | ||
| 3 years | -36.2% | +68.0% | −104.2 pts | -13.9% | +18.9% |
| 5 years | -83.7% | +66.2% | −149.9 pts | -30.5% | +10.7% |
| 10 years | -84.2% | +291.3% | −375.5 pts | -16.8% | +14.6% |
Fourteen years at a glance
Fiscal years 2012 to 2025 and trailing twelve months, USD
Revenue
Net income
EPS, diluted
Free cash flow
Press releases
Releases Oxbridge Re filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Results
About Oxbridge Re
Fire, Marine & Casualty Insurance
Oxbridge Re Holdings Limited is a specialty property and casualty reinsurer that provides reinsurance solutions through its operating subsidiaries. The company specializes in underwriting fully collateralized reinsurance contracts designed to protect property and casualty insurance companies against medium-frequency, high-severity property catastrophe risks. In addition to traditional reinsurance operations supported by a reinsurance sidecar, the company develops and issues tokenized reinsurance securities and Web3-focused products representing fractionalized interests in underlying reinsurance contracts and other real-world assets. Its primary customers are property and casualty insurers seeking catastrophe protection.
Company profile, executives and historyOxbridge Re stock: common questions
What is Oxbridge Re's stock price?
OXBR closed at $0.72 on Nov 18, 2026, up 0.00% on the day. Over the past 52 weeks it traded between $0.65 and $1.86.
What is Oxbridge Re's market cap?
Oxbridge Re was worth $5.86M at the close on Nov 18, 2026: the share price times the diluted shares outstanding.
What is OXBR's P/E ratio?
OXBR trades at 36.0 times earnings, based on diluted earnings per share of $0.02 over the twelve months to Jun 30, 2026.
How much revenue does Oxbridge Re make?
Oxbridge Re reported revenue of $2.78M for the twelve months to Jun 30, 2026, up 40.4% from a year earlier.
Does Oxbridge Re pay a dividend?
No. Oxbridge Re has not paid a cash dividend over the last twelve months.
When does Oxbridge Re report earnings next?
Oxbridge Re is expected to report Q4 FY2026 results on Mar 29, 2027, during market hours. The date is estimated from its past reporting pattern until the company confirms it.
How has OXBR stock performed over the past year?
Including dividends, OXBR returned -40.5% over the past year, against +11.8% for the S&P 500.
Who are Oxbridge Re's competitors?
Companies most similar to Oxbridge Re by business, industry and size include KG, PRHI, MHLA, ACIC, HRTG.
See a number that looks wrong?